Abstract 301P
Background
Cervical cancer is the most prevalent reproductive malignancy in women worldwide and estimated over 600,000 new cases and 340,000 deaths each year. Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer. Despite the great improvement this strategy has achieved, nearly 30% of patients will suffer distant metastases and 70% of patients may experience local recurrence. The dominance of Lactobacillus in the vaginal microenvironment of healthy women helps to establish a physiological barrier on the vaginal surface, Microbial biomarkers are effective for predicting the nonresponse for immune checkpoint inhibitor administration. It is intriguing to explore the alteration of vaginal microbial community challenged by chemoradiotherapy, also whether microorganism(s) could be used as biomarkers to predict the responsiveness of chemoradiotherapy.
Methods
A total of 126 patients with IB-IVB cervical cancer who received chemoradiotherapy in our hospital were enrolled in this study. The sampling of vaginal microbiome was carried out as we previously described, both pre- and post-treatment of each patient. Bacterial genomic DNA was extracted and 16S rRNA was sequenced from their vaginal secretions, and the results were analyzed bioinformatically.
Results
We found that the structure and composition of the vaginal microbiome changed significantly before and after radiotherapy, and radiotherapy treatment significantly changed the structure of the microorganisms, destroyed their physiological functions and disrupted the homeostasis of the microbial community. At the same time, we found that the beneficial microbial community in the vaginal microbiome decreased significantly in the relapsing group compared with the non-relapsing group before and after radiotherapy, and the microbial function and community homeostasis were significantly reduced, suggesting an unhealthy vaginal microbiome in the relapsing group.
Conclusions
We have shown that C-reactive protein and disease stage and other factors and biomarkers (such as L. iners) are important factors in predicting the recurrence of cervical cancer patients after radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Zhejiang medicine and health science and technology project.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract